Alexion shelves an early-stage Sanfilippo B drug, writes off $85M
When Alexion bought out Synageva in an $8.4 billion deal a little less than two years ago, the big attraction was Kanuma, a rare disease drug that went on to an approval. But there was one notable pipeline therapy, SBC-103 for rare cases of Sanfilippo B, that drew some attention for the valuation.
Until today. Alexion said in its 2016 review that it is stopping work on SBC-103, a recombinant form of the NAGLU enzyme, taking an $85 million write-off. Here’s the burial announcement:
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
